Movalis: instructions for using injections and what it is needed for, price, reviews, analogues. Medicine Movalis: indications for use, contraindications, analogues

Description and instructions for Movalis tab. 7.5 mg No. 20:

Instructions for use

Movalis tab. 7.5 mg No. 20

Dosage forms

tablets 7.5 mg

Synonyms

Amelotex
Arthrozan
Bi-xicam
Melbek
Melbek forte
Melox
Meloxicam
MELOXICAM AVEXIMA
Meloxicam DS
Meloxicam Canon
Meloxicam Stada
Meloxicam-OBL
Meloxicam-Prana
Meloxicam-Teva
Meloflex Rompharm
Mesipol
Mirlox
Movasin
Oxycamox

Group
Anti-inflammatory drugs - oxicams

International generic name
Meloxicam

Compound
Active ingredient: meloxicam 15 mg.

Manufacturers
Boehringer Ingelheim Espana S.A (Spain)

pharmachologic effect
Pharmacodynamics. The drug is a non-steroidal anti-inflammatory drug (NSAID), belongs to enolic acid derivatives and has anti-inflammatory, analgesic and antipyretic effects. The pronounced anti-inflammatory effect of meloxicam has been established in all standard models of inflammation. The mechanism of action of meloxicam is its ability to inhibit the synthesis of prostaglandins, known mediators of inflammation. Meloxicam in vivo inhibits the synthesis of prostaglandins at the site of inflammation to a greater extent than in the gastric mucosa or kidneys. These differences are due to more selective inhibition of cyclooxygenase-2 (COX-2) compared with cyclooxygenase-1 (COX-1). Inhibition of COX-2 is thought to mediate the therapeutic effects of NSAIDs, whereas inhibition of the constitutively present isoenzyme COX-1 may be responsible for gastric and renal side effects. The selectivity of meloxicam for COX-2 has been confirmed in various test systems, both in vitro and in vivo. The selective ability of meloxicam to inhibit COX-2 was demonstrated when using human whole blood as a test system in vitro. It was found that meloxicam (in doses of 7.5 mg and 15 mg) more actively inhibited COX-2, having a greater inhibitory effect on the production of prostaglandin E2 stimulated by lipopolysaccharide (reaction controlled by COX-2) than on the production of thromboxane, which is involved in the coagulation process blood (reaction controlled by COX-1). These effects were dose dependent. Ex vivo studies have shown that meloxicam (at doses of 7.5 mg and 15 mg) has no effect on platelet aggregation and bleeding time. In clinical studies, side effects from gastrointestinal tract(GI) generally occurred less frequently with meloxicam 7.5 and 15 mg than with other NSAIDs compared. This difference in the frequency of side effects from the gastrointestinal tract is mainly due to the fact that when taking meloxicam, such phenomena as dyspepsia, vomiting, nausea, and abdominal pain were observed less frequently. The incidence of upper gastrointestinal perforations, ulcers and bleeding associated with meloxicam use was low and dose dependent. Pharmacokinetics. Absorption. Meloxicam is completely absorbed after intramuscular administration. Relative bioavailability compared to oral bioavailability is almost 100%. Therefore, when switching from injection to oral forms, dose selection is not required. After administration of the drug 15 mg of the drug intramuscularly, a peak plasma concentration of about 1.6 - 1.8 μg / ml is achieved within approximately 60 - 96 minutes. Distribution. Meloxicam binds well to plasma proteins, especially albumin (99%). Penetrates into synovial fluid, the concentration in synovial fluid is approximately 50% of the concentration in plasma. The volume of distribution is low, approximately 11 L. Interindividual differences range from 7 to 20%. Metabolism. Meloxicam is almost completely metabolized in the liver to form 4 pharmacologically inactive derivatives. The main metabolite, 5"-carboxymeloxicam (60% of the dose), is formed by oxidation of the intermediate metabolite, 5"-hydroxymethylmeloxicam, which is also excreted, but to a lesser extent (9% of the dose). In vitro studies have shown that in this metabolic transformation important role plays the CYP2C9 isoenzyme, additional meaning has the CYP3A4 isoenzyme. Peroxidase is involved in the formation of the other two metabolites (constituting, respectively, 16% and 4% of the drug dose), the activity of which probably varies individually. Excretion. It is excreted equally through the intestines and kidneys, mainly in the form of metabolites. In unchanged form, less than 5% of the daily dose is excreted in feces; in urine, unchanged, the drug is found only in trace amounts. The average half-life varies from 13 to 25 hours. Plasma clearance averages 7 - 12 ml/min after a single dose. Meloxicam demonstrates linear pharmacokinetics in doses of 7.5 - 15 mg when administered intramuscularly. Insufficiency of liver and/or kidney function. Insufficiency of liver function, as well as mild renal failure, do not have a significant effect on the pharmacokinetics of meloxicam. The rate of excretion from the body is significantly higher in patients with moderate renal failure. Meloxicam binds less well to plasma proteins in patients with end-stage renal failure. In end-stage renal disease, increased volume of distribution may result in higher concentrations of free meloxicam, so in these patients daily dose should not exceed 7.5 mg. Elderly patients. Elderly patients compared to young patients have similar pharmacokinetic parameters. In elderly patients, the average plasma clearance during steady-state pharmacokinetics is slightly lower than in younger patients. Elderly women have higher AUG (area under the concentration-time curve) values and a longer half-life compared to younger patients of both sexes.

Side effect
Side effects that were considered possible to be associated with the use of the drug are described below. Within systemic organ classes, the following categories are used according to the frequency of side effects: very often (> 1/10); often (> 1/100,< 1/10); нечасто (> 1/1,000, < 1/100); редко (> 1/10,000, < 1/1,000); очень редко (< 1/10,000); не установлено. Нарушения со стороны крови и лимфатической системы: нечасто - анемия; редко - лейкопения, тромбоцитопения, изменения числа клеток крови, включая изменения лейкоцитарной формулы. Нарушения со стороны иммунной системы: нечасто - другие реакции гиперчувствительности немедленного типа; не установлено - анафилактический шок, анафилактоидные/анафилактические реакции. Нарушения психики: редко - изменение настроения; не установлено - спутанность сознания, дезориентация. Нарушения со стороны нервной системы: часто - headache; infrequently - dizziness, drowsiness. Visual, hearing and labyrinthine disorders: infrequently - vertigo; rarely - conjunctivitis, visual impairment, including blurred vision, tinnitus. Disorders of the heart and blood vessels: infrequently - increased blood pressure, a feeling of a “rush” of blood to the face; rarely - palpitations. Violations by respiratory system: rarely - bronchial asthma in patients with allergies to acetylsalicylic acid and other NSAIDs. Gastrointestinal disorders: often - abdominal pain, dyspepsia, diarrhea, nausea, vomiting; uncommon - hidden or obvious gastrointestinal bleeding, gastritis, stomatitis, constipation, bloating, belching; rarely - gastroduodenal ulcers, colitis, esophagitis; very rarely - perforation of the gastrointestinal tract. Disorders of the liver and biliary tract: Uncommon - transient changes in liver function tests (for example, increased activity of transaminases or bilirubin); very rarely - hepatitis. Disorders of the skin and subcutaneous tissues: infrequently - angioedema, itching, skin rash; rarely - toxic epidermal necrolysis, Stevens-Johnson syndrome, urticaria; very rarely - bullous dermatitis, erythema multiforme; not established - photosensitivity. Renal and urinary tract disorders: uncommon - changes in renal function (increased levels of creatinine and/or urea in the blood serum), urinary disorders, including acute urinary retention; very rarely - acute renal failure. General disorders and disorders at the injection site: often - pain and swelling at the injection site; infrequently - swelling. Concomitant use with drugs that depress Bone marrow(eg methotrexate) may cause cytopenia. Gastrointestinal bleeding, ulceration, or perforation can be fatal. As with other NSAIDs, the possibility of interstitial nephritis, glomerulonephritis, renal medullary necrosis, and nephrotic syndrome cannot be excluded.

Indications for use
Initial period of treatment of pain syndrome and short-term symptomatic therapy of rheumatoid arthritis, osteoarthritis (arthrosis, degenerative joint diseases), ankylosing spondylitis.

Contraindications
Hypersensitivity to the active ingredient or auxiliary components of the drug. There is a possibility of cross-sensitivity from acetylsalicylic acid to other NSAIDs; Hypersensitivity (including to other non-steroidal anti-inflammatory drugs), complete or incomplete combination bronchial asthma, recurrent nasal or sinus polyposis and intolerance acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (including history); Erosive and ulcerative lesions of the stomach and duodenum in the acute stage or recently transferred; Inflammatory bowel disease - Crohn's disease or ulcerative colitis in the acute stage; severe liver and heart failure; severe renal failure (if hemodialysis is not performed, creatinine clearance is less than 30 ml/min, and also with confirmed hyperkalemia), progressive kidney disease; active liver disease; active gastrointestinal bleeding, recent cerebrovascular bleeding or established diagnosis of diseases of the blood coagulation system; age under 18 years; pregnancy; lactation period; therapy of perioperative pain during coronary artery bypass grafting; Concomitant therapy with anticoagulants, as there is a risk of intramuscular hematoma formation.

Directions for use and dosage

Osteoarthritis: 7.5 mg per day. If necessary, this dose can be increased to 15 mg per day. Rheumatoid arthritis: 15 mg per day. Depending on the therapeutic effect, this dose may be reduced to 7.5 mg per day. Ankylosing spondylitis: 15 mg per day. Depending on the therapeutic effect, this dose may be reduced to 7.5 mg per day. In patients with an increased risk of adverse reactions, it is recommended to begin treatment with a dose of 7.5 mg per day. In patients with severe renal failure on hemodialysis, the dose should not exceed 7.5 mg per day. General recommendations. Since the potential risk of adverse reactions depends on the dose and duration of treatment, the lowest possible dose and duration of use should be used. The maximum recommended daily dose is 15 mg. Combined use. The drug should not be used simultaneously with other NSAIDs. The total daily dose of the drug used in different dosage forms should not exceed 15 mg. Teenagers. Maximum dose in adolescents it is 0.25 mg/kg. As a general rule, the drug should only be used in adolescents over 12 years of age and adults. The total daily dose should be taken in one dose, during meals, with water or other liquid.

Overdose
There is insufficient data on cases associated with drug overdose. Symptoms characteristic of an NSAID overdose are likely to be present in severe cases: drowsiness, disturbances of consciousness, nausea, vomiting, epigastric pain, gastrointestinal bleeding, acute renal failure, changes in blood pressure, respiratory arrest, asystole. Treatment: no known antidote. In case of drug overdose, symptomatic therapy should be used. Cholestyramine is known to accelerate the elimination of meloxicam.

Interaction
Other prostaglandin synthesis inhibitors, including glucocorticoids and salicylates - simultaneous administration with meloxicam increases the risk of ulceration in the gastrointestinal tract and gastrointestinal bleeding (due to synergistic action). Concomitant use with other NSAIDs is not recommended. Anticoagulants for oral administration, heparin for systemic use, thrombolytic agents - simultaneous use with meloxicam increases the risk of bleeding. In case of simultaneous use, careful monitoring of the blood coagulation system is necessary. Antiplatelet drugs, serotonin reuptake inhibitors - simultaneous use with meloxicam increases the risk of bleeding due to inhibition of platelet function. In case of simultaneous use, careful monitoring of the blood coagulation system is necessary. Lithium preparations - NSAIDs increase the level of lithium in plasma by reducing its excretion by the kidneys. The simultaneous use of meloxicam with lithium preparations is not recommended. If simultaneous use is necessary, careful monitoring of plasma lithium concentrations is recommended throughout the course of lithium use. Methotrexate - NSAIDs reduce the secretion of methotrexate by the kidneys, thereby increasing its plasma concentration. The simultaneous use of meloxicam and methotrexate (at a dose of more than 15 mg per week) is not recommended. In case of simultaneous use, careful monitoring of renal function and blood count is necessary. Meloxicam may increase the hematological toxicity of methotrexate, especially in patients with impaired renal function. Contraception - there is evidence that NSAIDs may reduce the effectiveness of intrauterine contraceptive devices, but this has not been proven. Diuretics - the use of NSAIDs in case of dehydration of patients is accompanied by the risk of developing acute renal failure. Antihypertensive drugs (beta-blockers, angiotensin-converting enzyme inhibitors, vasodilators, diuretics). NSAIDs reduce the effect of antihypertensive drugs due to inhibition of prostaglandins, which have vasodilating properties. Angiotensin II antagonists receptors, when co-administered with NSAIDs, increase the reduction in glomerular filtration, which can thereby lead to the development of acute renal failure, especially in patients with impaired renal function. Cholestyramine, by binding meloxicam in the gastrointestinal tract, leads to its more rapid elimination. NSAIDs, by acting on renal prostaglandins, may enhance the nephrotoxicity of cyclosporine. When using drugs together with meloxicam that have a known ability to inhibit CYP2C9 and/or CYP3A4 (or are metabolized with the participation of these enzymes), the possibility of pharmacokinetic interaction should be taken into account. The possibility of interaction with antidiabetic drugs for oral administration cannot be excluded. With the simultaneous use of antacids, cimetidine, digoxin and furosemide, no significant pharmacokinetic interactions were identified.

special instructions
Pregnancy and lactation period. The use of the drug is contraindicated during pregnancy. NSAIDs are known to penetrate into breast milk Therefore, the use of the drug during breastfeeding is contraindicated. As a drug that inhibits cyclooxygenase/prostaglandin synthesis, Movalis may have an effect on fertility and is therefore not recommended for women planning pregnancy. Meloxicam may delay ovulation. In this regard, in women who have problems conceiving and are undergoing examination for similar problems, it is recommended to stop taking the drug. Patients suffering from diseases of the gastrointestinal tract should be monitored regularly. If ulcerative lesions of the gastrointestinal tract or gastrointestinal bleeding occur, the drug must be discontinued. Gastrointestinal ulcers, perforation or bleeding may occur during treatment at any time, either in the presence of warning symptoms or a history of serious gastrointestinal complications, or in the absence of these signs. The consequences of these complications are generally more serious in older people. When using NSAIDs, serious skin reactions such as exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis may develop. Therefore, special attention should be paid to patients reporting the development of adverse events from the skin and mucous membranes, as well as hypersensitivity reactions to the drug, especially if such reactions were observed during previous courses of treatment. The development of such reactions is observed, as a rule, during the first month of treatment. If the first signs appear skin rash, changes in mucous membranes or other signs of hypersensitivity, discontinuation of use should be considered. Cases have been described when taking NSAIDs to increase the risk of developing serious cardiovascular thrombosis, myocardial infarction, angina, possibly fatal. This risk increases with long-term use of the drug, as well as in patients with a history of the above diseases and those predisposed to such diseases. NSAIDs inhibit the synthesis of prostaglandins in the kidneys, which are involved in maintaining renal perfusion. The use of NSAIDs in patients with reduced renal blood flow or reduced circulating blood volume may lead to decompensation of latent renal failure. After discontinuation of NSAIDs, renal function usually returns to baseline levels. Those most at risk for developing this reaction are elderly patients, patients with dehydration, congestive heart failure, cirrhosis, nephrotic syndrome or acute renal impairment, patients concomitantly taking diuretics, ACE inhibitors, angiotensin II receptor antagonists, as well as patients who have undergone major surgical interventions that lead to hypovolemia. In such patients, diuresis and renal function should be carefully monitored when initiating therapy. The use of NSAIDs in combination with diuretics can lead to sodium, potassium and water retention, as well as a decrease in the natriuretic effect of diuretics. As a result, predisposed patients may experience increased signs of heart failure or hypertension. Therefore, such patients should be closely monitored and adequate hydration maintained. Before starting treatment, a kidney function test is necessary. In case of combination therapy, renal function should also be monitored. When using the drug (as well as most other NSAIDs), episodic increases in serum transaminase activity or other indicators of liver function are possible. In most cases, this increase was small and transitory. If the detected changes are significant or do not decrease over time, the drug should be discontinued and the detected laboratory changes should be monitored. Weakened or malnourished patients may be less able to tolerate adverse events and should therefore be monitored closely. Like other NSAIDs, the drug may mask the symptoms of an underlying infectious disease. As a drug that inhibits cyclooxygenase/prostaglandin synthesis, the drug may have an effect on fertility and is therefore not recommended for women who have difficulty conceiving. In this regard, in women undergoing examination for this reason, discontinuation of the drug is recommended. In patients with mild or moderate renal impairment (creatinine clearance more than 25 ml/min), no dose adjustment is required. In patients with liver cirrhosis (compensated), no dose adjustment is required. Influence on the ability to drive a car and other mechanisms. No special clinical studies have been conducted on the effect of the drug on the ability to drive a car or use machinery. However, when driving or operating machinery, the possibility of dizziness, drowsiness, visual impairment or other disorders of the central nervous system should be taken into account. During treatment, patients should be careful when managing vehicles and occupation of others potentially dangerous species activities that require increased concentration and speed of psychomotor reactions.

Storage conditions
Store in a place protected from light, out of reach of children, at a temperature not exceeding 30 C.

Movalis (lat. Movalis) is an original drug developed by the German company Boehringer Ingelheim GmbH.

The active substance is meloxicam, which is a partially selective non-steroidal anti-inflammatory drug. Available in the form of tablets, suspensions, rectal suppositories and injections. It has a pronounced anti-inflammatory and analgesic effect.

In comparison with analogues, it is characterized by less toxic effects on the digestive tract, liver and cardiovascular system. Prescribed for inflammatory diseases of the joints and spine.

The era of NSAIDs began in 1897, when the German chemist F. Hoffmann managed to synthesize the first drug with analgesic and antipyretic properties - acetylsalicylic acid.

The product received the trade name “Aspirin” and began to be actively used in medical practice. At the beginning of the 20th century. Other compounds have been developed with similar therapeutic effect: phenacetin, paracetamol, amidopyrine, analgin.

Many years of experience in the use of the first NSAIDs have proven their high effectiveness in various types of treatment. inflammatory diseases. At the same time, it was discovered that long-term therapy with them often provokes damage to the mucous membranes of the digestive tract. These observations prompted the search for new, safer analgesics.

An important milestone in the history of the class was the discovery of the English pharmacologist J. Vane, who in 1971 established that the effects of NSAIDs are due to the blockade of a special enzyme in the body - cyclooxygenase (COX).

It turned out that the enzyme has 2 varieties, one of which is responsible for the formation of the inflammatory reaction, the other for the synthesis of protective mucus in the stomach.

Suppression of the activity of “bad” cyclooxygenase (COX-2) leads to the development of anti-inflammatory, analgesic and antipyretic effects, and inhibition of “good” (COX-1) is accompanied by side effects. The data obtained formed the basis for the development of modern NSAIDs with high selectivity for COX-2.

In 1985, the first partially selective drug, nimesulide (“Aulin”), entered the pharmaceutical market. And in the late 80s, Boehringer Ingelheim specialists obtained a formula for melokisikam, which had even higher selective activity.

In 1993, the company's veterinary division (Boehringer Vetmedica) released meloxicam for use in dogs. The drug was registered under the brand name Metacam in the UK and Germany.

In 1995, the development of dosage forms of meloxicam for humans was completed. Under the Movalis brand, the product became available to consumers in several European countries. By the end of 2000, the drug was approved for use in more than 40 countries, including the USA, Japan and Canada.

Properties of the active substance

International nonproprietary name: meloxicam (Latin and English Meloxikam).

Chemical name according to IUPAC nomenclature: 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide.

Structural formula:

Gross formula: C14H13N3O4S2

Molecular weight: 351.4

Meloxicam is a light yellow amorphous powder, insoluble in water, highly soluble in acids, alkalis and ethanol. Density - 1.614 g/cu. cm. Refractive index - 1.72. According to its chemical structure, the compound belongs to the oxicam group.

Clinical data

The effectiveness and safety of Movalis have been confirmed in 230 clinical trials, in which a total of more than 30 thousand patients took part.

The largest multicenter randomized study MELISSA (1998, Hawkey C., Steinbruck K.) included 9300 volunteers with osteoarthritis. Patients in one group were given Movalis at a dose of 15 mg/day, patients in the other group were given sustained-release diclofenac at a dose of 100 mg/day.

Treatment continued for 28 days. Both drugs showed equivalent effectiveness, but Movalis was 1.5 times less likely to cause adverse reactions from the gastrointestinal tract.

One of the studies (2001, Gagnier P., Reed J.I., Singh G.) was devoted to comparing the effectiveness of Movalis with a number of other NSAIDs (diclofenac, ibuprofen, rofecoxib, piroxicam). 1309 patients with rheumatoid arthritis took part in the experiment.

The first group took meloxicam at a dose of 7.5 mg/day, the second group took any other NSAID at an average therapeutic dose. The results showed that the use of Movalis was effective in 67% of patients, while therapy with other drugs was successful in only 54% of volunteers.

In 1999, a group of American researchers (Chen Y.F., Barton P., Jobanputra P.) published a systematic review that compared the effectiveness of meloxicam and non-selective NSAIDs.

Scientists assessed data from 14 international clinical studies. Their analysis confirmed that the analgesic and anti-inflammatory activity of Movalis is comparable to traditional NSAIDs.

At the same time, the drug compares favorably with its predecessors in its lower incidence of complications from the digestive tract. So, if when taking diclofenac, naproxen or piroxicam, the development of gastropathy is observed on average in 17-19% of patients, then when treated with Movalis - no more than 11%.

Composition, release forms, packaging

The drug is available in the form:

1.5% oral suspension,
tablets containing the active substance 7.5 mg and 15 mg,
1.5% solution for intramuscular injection,
rectal suppositories containing the active substance 7.5 mg and 15 mg.

Sucrose is excluded from the auxiliary composition of the suspension, which makes it possible to use it in patients with diabetes mellitus. The liquid is packaged in glass bottles of 100 ml and then, together with a dosing spoon, in cardboard packaging.

The injection solution is poured into ampoules of 1.5 ml. 3 or 5 ampoules are placed in cardboard packs.

The tablets are contained in foil blisters. One consumer package contains 10 or 20 tablets.

Candles are packaged in polymer contour packaging and then in cardboard packs of 6 or 12 pieces.

Mechanism of action

The therapeutic effects of meloxicam are due to its ability to suppress the activity of cyclooxygenase type 2 (COX 2), an enzyme responsible for the synthesis of inflammatory mediators. Blockade of the enzyme leads to inhibition of the inflammatory reaction, a pronounced weakening of the pain syndrome and a slight decrease in temperature in the pathological focus.

In a number of laboratory experiments, it has been proven that when used in low doses, Movalis has virtually no effect on the activity of a related enzyme - cyclooxygenase 1, which regulates important physiological processes in organism:

formation of protective mucus in the stomach,
synthesis of blood clotting factors,
perfusion (filling with blood) of the renal vessels.

In this regard, the drug practically does not cause adverse reactions from the gastrointestinal tract, cardiovascular system and kidneys.

When used in high doses, the selectivity of meloxicam for COX 2 decreases, as a result of which the risks of negative effects increase.

Metabolism and excretion

When administered enterally (using tablets/suspension/suppositories), the drug is easily and quickly absorbed through the mucous membranes of the digestive tract. Up to 89% of the dose taken enters the bloodstream. The maximum concentration in plasma is observed 5-6 hours after administration. A stable concentration is achieved on days 3-5 of therapy, which lengthens the time to achieve a lasting clinical effect.

A faster analgesic effect can be achieved when using Movalis parenteral solution. When administered intramuscularly, the drug is quickly absorbed into the blood. The maximum concentration in plasma is reached after 1.5 hours. The indicator remains stable over the next 5-6 hours. In the blood, up to 90% of the drug is in a protein-bound state.

Meloxicam is biotransformed in the liver to form 4 inactive metabolites, which are excreted from the body in urine and feces. The half-life is 20 hours.

In patients with moderate renal or hepatic impairment, the pharmacokinetics of Movalis remain virtually unchanged. In elderly people, the drug is metabolized somewhat more slowly than in young people.

Indications for use

In Russia, the registered indications for the use of Movalis are:

osteoarthritis,
rheumatoid arthritis,
ankylosing spondylitis (Bechterew's disease).

IN European countries the drug is also prescribed for the symptomatic treatment of any other inflammatory diseases of the joints, spine and primary dysmenorrhea.

Contraindications

Therapy should not be carried out in the following conditions:

hypersensitivity to NSAIDs,
allergic reaction to any of the auxiliary components of the drug,
severe renal, hepatic or cardiovascular failure,
exacerbation peptic ulcer digestive tract,
history of aspirin asthma,
simultaneous therapy with anticoagulants (injection only).

Due to insufficient knowledge, the drug is not recommended for use in childhood (suppositories are contraindicated for children under 12 years of age, tablets and suspension for children under 15 years of age, injections for children under 18 years of age).

Use during pregnancy and lactation

Movalis penetrates the placental barrier and into breast milk. It is believed that the drug may increase the risks of spontaneous abortion and the development of heart defects in the fetus, so its use in pregnant women is unacceptable. The effect of meloxicam on children has not been studied, and therefore therapy during lactation is also considered contraindicated.

Impact on the ability to drive vehicles and other complex mechanisms

There have been no special studies on how Movalis affects the ability to drive. However, when using the drug, the possibility of developing such negative reactions as drowsiness, dizziness and visual impairment should be taken into account. Patients are advised to exercise caution when engaging in any potentially hazardous activities.

Directions for use and doses

Movalis is used orally, rectally or intramuscularly.

Intramuscular administration is indicated for acute pain syndrome during the first 2-3 days of therapy. Further treatment is continued with oral or rectal forms. Recommended doses are 7.5 or 15 mg per day.

Tablets, suspension or suppositories are prescribed:

for osteoarthritis - 7.5 mg per day,
for rheumatoid arthritis and ankylosing spondylitis - 15 mg per day.

At the discretion of the doctor, dosages can be adjusted up or down.

Side effects

More than 1% of patients when taking Movalis may experience:

dyspeptic disorders (nausea, vomiting, diarrhea),
anemia,
skin itching,
headache,
the appearance of edema.

In 0.1-1% of patients in clinical studies the following were observed:

development of reflux esophagitis,
stomatitis,
decrease in the level of leukocytes and platelets in the blood,
drowsiness,
dizziness,
tachycardia,
increased blood pressure.

In less than 0.1% of cases the following were recorded:

ulcerative lesions of the digestive tract,
gastritis,
photosensitivity,
mood swings,
visual disturbances,
conjunctivitis,
renal failure,
anaphylactic reactions.

When administered parenterally, swelling and pain may occur at the injection site.

Overdose

There is insufficient data on meloxicam poisoning. Presumably, an overdose is manifested by lethargy, nausea, vomiting, acute abdominal pain, increased blood pressure, and tachycardia. Treatment is carried out symptomatically. The elimination of the drug is accelerated by cholestyramine.

special instructions

During therapy, special caution must be observed in patients with diseases of the digestive tract. If ulcerative lesions or bleeding are suspected, the drug should be discontinued immediately. The most severe complications from the gastrointestinal tract occur in elderly people.

Taking Movalis may cause severe skin reactions(exfoliative dermatitis, toxicoderma), therefore, when the first signs of rash appear, the course of treatment must be interrupted and consult your doctor. Patients with hypersensitivity to NSAIDs should be especially careful.

With long-term use of meloxicam, the risk of increased frequency of angina attacks, myocardial infarction and thrombosis increases. This is important to consider when prescribing the drug to patients with a predisposition to cardiovascular disorders.

In patients with renal failure, dehydration, liver cirrhosis, congestive heart failure, taking diuretics and antihypertensive drugs, renal function should be monitored during treatment.

In rare cases, Movalis may cause a short-term increase in liver transaminases. If the detected changes are significant, it is better to stop taking the drug.

Due to its anti-inflammatory and antipyretic effect, meloxicam can mask the symptoms of infectious diseases.

Like all NSAIDs, Movalis reduces fertility levels, so it is not recommended for women planning to conceive.

Patients with mild to moderate renal or hepatic impairment do not need to adjust the dose of the drug.

Interaction with other drugs

Concomitant use of Movalis with other NSAIDs, corticosteroids or serotonin reuptake inhibitors increases the risk of gastric bleeding.

Meloxicam increases the toxicity of methotrixate and lithium preparations, therefore, when combined therapy, the doses of the latter are recommended to be reduced to the minimum possible.

Like other NSAIDs, Movalis reduces the effectiveness of:

oral contraceptives,
beta blockers,
diuretics,
ACE inhibitors,
calcium channel blockers.

The use of meloxicam in combination with diuretics, angiotensin receptor antagonists or cyclosporine increases the likelihood of developing renal failure.

It is assumed that Movalis may influence the pharmacokinetics of hypoglycemic drugs.

It has been reliably established that the product does not interact with antacids, digoxin, cimetidine.

Vacation conditions

On prescription.

Storage

In a dry place, protected from light. Suppositories and solution for injection - at a temperature not exceeding 30ºС, suspension and tablets - at a temperature not exceeding 25ºС. Keep away from children.

Best before date

For suppositories and suspensions - 3 years.

For tablets and solution for injection - 5 years.

After opening the bottle, the suspension is stored for no more than 6 months.

Countries in which it applies

As of 2015, Movalis is used in 48 countries, including:

Russia,
Belarus,
Ukraine,
Canada,
China,
Japan,
Austria,
Germany,
Australia,
France,
Italy,
a number of African and Middle Eastern states.

In the markets of some European, Asian countries and the USA, the drug is sold under the Mobic brand.

In Russia, Movalis was registered and approved for sales by the Ministry of Health of the Russian Federation in 1996.

In the USA, the drug was evaluated by the FDA and began to be used in 2000.

Manufacturer

The right to produce and sell Movalis belongs to the German corporation Boehringer Ingelheim GmbH, which is one of the twenty largest pharmaceutical companies in the world. The company has 146 branches located in 45 countries. The main activities of Beringer are the development and production of new medicines for medical and veterinary practice. Every year the company allocates more than 1/5 of its profits to scientific research.

The production of Movalis suspension and tablets is currently carried out by the German division of the Boehringer Ingelheim GmbH corporation, the production of injections by the Spanish branch of Boehringer Espana, and the production of suppositories by the Italian subsidiary Institut de Angeli. All of the company's factories are certified in accordance with the rules of the international CMP standard.

Analogues

More than 30 generics (medicinal copies) of Movalis are registered on the Russian market.

According to analytical companies, the most popular among them are:

Arthrozan,
Meloxicam,
Movasin,
Melox,
Meloxicam Pfizer,
Meloxicam DS,
Amelotex,
Melbek,
Mataren.

The active ingredient of all of these drugs is also meloxicam. However, products from different companies have different production technologies and compositions of auxiliary components, and therefore may differ from each other in effectiveness and frequency of adverse reactions.

The main advantage of Movalis over its analogues is the presence of a good evidence base. To date, this is the only meloxicam drug whose safety and effectiveness have been confirmed in large-scale clinical studies.

Some analogues of Movalis and their manufacturers:

Treatment of diseases of the musculoskeletal system

Trade name of the drug	Release forms	Manufacturing company
Arthrozan	Solution 0.6% for intramuscular administration Tablets of 7.5 and 15 mg	Pharmstandard (Russia)
Lem	Tablets 7.5 mg and 15 mg	Pharmaceutical enterprise "Obolenskoe" (Russia)
Movasin	1% solution for intramuscular administration Tablets of 7.5 mg and 15 mg	Synthesis (Russia)
Amelotex	1% solution for intramuscular administration Tablets 7.5 and 15 mg Suppositories 7.5 and 15 mg Gel 1% for external use

Science does not stand still. Bone diseases have become younger and this has become the reason for the development of drugs aimed at the human musculoskeletal system. One of these drugs is Movalis, which is produced in the form of tablets, injections, and rectal suppositories. Movalis tablets were first registered as a drug for diseases of the musculoskeletal system in 2006.

The active substance is MELOXICAM. There is no better drug than Movalis. It has a very gentle effect on the sore spot and quickly restores joint mobility.

The tablets are produced in original packaging containing 20 tablets of 15 mg of active substance (two blisters of 10 pieces or one of 20 pieces) or 20 tablets of 7.5 mg. The drugs are dispensed according to a doctor's prescription.

Movalis is a tablet yellow color(pale yellow). They are round with a convex side that has a logo; on the other, concave side, there is a concave line that separates the “77C” engraving on both halves.

The tablet contains additional substances:

Sodium citrate
Microcrystalline cellulose
Colloidal silicon dioxide
Kollidon 25
Lactose
Magnesium stearate
Crospovidone

The tablets contain lactose; if the patient is intolerant to this substance, then the use of Movalis should be discontinued.

Tablets must be stored in a dry place. Storage temperature 25 degrees. The shelf life of the tablets is limited to 5 years.

The drug belongs to the oxicam class. It has the following effects: analgesic, anti-inflammatory, antipyretic. This is due to the fact that the biosynthesis of prostaglandites decreases as a result of the fact that the enzymatic activity of COX (cyclooxygenase) is inhibited. Meloxicam actively acts mainly on COX-2, which takes part in the synthesis of prostaglandites at the site of inflammation. This allows you to prevent side effects on upper sections Gastrointestinal tract, and in some way affects COX-1. The drug Movalis is chondroneutral.

Movalis finds its application not only in our country, but also abroad, which has been repeatedly covered in scientific works. The result of these works was the demonstration of the selectivity of meloxicam (Movalis) for the COX-2 isoenzyme, compared with such non-steroidal anti-inflammatory drugs as piroxicam, naproxen, and indomethacin.

After the drug is taken orally, food intake does not affect the absorption of meloxicam.

The concentration of the drug in plasma depends on the dose prescribed by the doctor. Only on days 3 - 5 does the plasma concentration reach a plateau and may not increase throughout the year. Almost all of meloxicam contained in plasma (99%) is conjugated with proteins. Daily fluctuations in the concentration of meloxicam are small if taken once a day.

Meloxicam easily penetrates into the synovial fluid and within sixty minutes after taking the first tablet, the drug concentration reaches up to 50% of the level in the blood plasma. The stronger the local joint inflammation, the greater the concentration of Movalis in the synovial fluid. The reactive metabolites into which meloxicam breaks down are excreted 50%/50% in feces and urine.

Kidney and liver failure medium degree do not affect the pharmacokinetic parameters of Movalis (meloxicam) tablets.

Movalis instructions for use

The drug is indicated for patients who suffer from:

Degenerative-dystrophic diseases of the CMA (osteochondrosis, arthrosis)
Autoimmune connective tissue diseases (rheumatoid arthritis).
Bechterew's disease and inflammation of the joints (arthritis)

The instructions provide for compliance with dosage standards. Since the daily dose is 15 mg, it is recommended to take the drug once a day from 7.5 mg to 15 mg.

Movalis is contraindicated for pregnant women. If problems arise during breastfeeding, you should stop breastfeeding and switch to artificial feeding.

People with a sick stomach should be careful if there is a history of the disease.

The use of Movalis, along with other drugs, reduces the effectiveness of antihypertensive drugs, such as vasodilators, ACE inhibitors, beta-blockers.

When using Movalis together with anticoagulants, there is a risk of bleeding.

The simultaneous use of Movalis with diuretics threatens renal failure in those patients who experience dehydration.

If the drug is used simultaneously with NSAIDs, stomach ulcers and stomach bleeding, which can be fatal.

The concentration of lithium in the blood plasma will increase if lithium preparations are taken with Movalis.

The elimination of meloxicam is accelerated if cholestyramine is used together with Movalis.

When used in conjunction with methotrexate, there is a possibility of enhancing the myelosuppressive effect. And together with cyclosporine, it becomes possible to enhance the nephrotoxic effect of cyclosporine.

Side effects of the drug

The use of Movalis causes side effects in the digestive system: nausea, vomiting, dyspepsia, diarrhea, constipation, abdominal pain, intestinal colic, stomatitis, esophagitis. In some cases, gastric erosions may occur.

By affecting the central nervous system, the drug can cause dizziness, tinnitus and headache.

The cardiovascular system, when exposed to Movalis, can increase arterial pressure, increase heart rate, cause swelling and hot flashes.

Urinary system: kidney functions change their functioning, this is evidenced by lab tests.

Changes may occur in the blood: signs of anemia, thrombocytopenia, and leukopenia appear.

Allergic reactions may occur: skin itching, bronchospasm, urticaria, photosensitivity, rash. As soon as the first signs of side effects appear, you should stop taking the medication and consult a doctor.

Movalis injections

Movalis injections more effectively relieve the inflammatory process and relieve pain in the sore joint. These are new generation drugs, their side effects are significantly reduced. Injections are prescribed once a day.

When the drug is injected into the muscle, it is quickly absorbed and begins its effect within thirty minutes. If Movalis is used, the concentration of meloxicam in plasma reaches its maximum in one and a half hours and does not change for six hours.

For use this drug people treat it without fear, because they are satisfied with the result obtained, since its effect is easily tolerated.

Initially, injections are used for three to six days, and then tablets or suppositories are prescribed for another twenty days. There may be another treatment option, when suppositories are used instead of ampoules, and then tablets containing 15 mg of meloxicam.

Movalis instructions for use provide for the advisability of using injections in the first few days when severe pain. An injection of deep penetration into a MUSCLE should never be injected into a vein.

Self-medication is not advisable; you should definitely consult a doctor who, seeing the type of disease, prescribes the right dosage drug. The treatment process is long, so you cannot increase the dose on your own in order to heal faster, this will lead to unwanted side effects. To avoid this, you should approach the use of the drug properly - take the minimum recommended dose for a short time.

Movalis in clinical trials

The drug Movalis is used in rheumatology and neurology. Movalis injections allow the use of step-by-step therapy for severe pain syndromes of various types.

In the orthopedic clinic, studies were carried out on the drug Movalis, which was used on early stage diseases of the musculoskeletal system after surgery. Patients after joint surgery experienced rapid recovery; the drug eliminated the symptoms of the disease and accelerated the return to normal life, full of physical activity.

Many authors of scientific papers suggest when acute pain use Movalis for three weeks, no less. They believe that this drug prevents pain memory from developing and prevents further exacerbation of the pain syndrome.

At the Department of Orthopedics, the drug Movalis was studied, using it after operations. Almost a hundred people were studied. The operations were different: on knee-joint, on the spine, hip joint, shoulder joint, foot.

After the operations, the joints became swollen, painful, and the body temperature increased. On the first day after surgery, patients were in intensive care and received NSAIDs and narcotic analgesics.

When transferred to the orthopedic department, half of the patients received Movalis injections and the other half received suppositories (15 mg). After three days, we switched to using tablets (15 mg) for another five days. The tolerability of the medication and the dynamics of swelling reduction were assessed.

All patients experienced a decrease in pain after Movalis. Some patients receiving injections felt relief after 17 minutes, while others who used suppositories felt less pain after 70 minutes. The analgesic effect of Movalis lasted six hours, without any tendency to decrease the effect.

Standard therapy in the department included the use of anticoagulants, vascular drugs, physiotherapeutic treatment and physical education. Movalis was used simultaneously with this treatment.

The advantage of Movalis (meloxicam) is that the drug is compatible with many medicines, which are used by older people for rheumatic, cardiovascular diseases and for impaired water-salt metabolism.

This study contributed to determining the tolerability of Movalis and the effectiveness of its use after orthopedic operations in the early postoperative period.

The muscle fiber damage indicator (MFD) is an important criterion for drug tolerability. Intramuscular injections lead to an increase in CPK levels, this is indicated by damaged muscles, released histamine, and chemotoxicity. Based on the study data, the concentration of CPK increased by 147%, for piroxicam, and for diclofenac - by 922%. When Movalis was injected into the muscle, no increase in CPK levels was observed.

Much attention is paid to the effect of non-steroidal anti-inflammatory drugs on metabolic processes in cartilage in patients with osteoarthritis. Experimental studies have shown that Movalis does not negatively affect the metabolism of proteoglycans in human cartilage explants and does not damage active reparative processes of cartilage in any pathology.

Movalis is a round tablet with one beveled side, yellow and pale yellow in color. Often the manufacturer's mark is located on the raised area. The drug belongs to enolic acid derivatives, as well as non-steroidal drugs that have antipyretic and anti-inflammatory effects on the body.

The main principle of its action is that the drug inhibits the synthesis of inflammatory mediators (in this case, prostaglandins).

Most often, elderly people with joint diseases resort to the help of Movalis. Joint damage is the most common problem, which in most cases leads to loss of performance. Osteochondrosis, arthritis, etc. in an advanced form, they greatly complicate life and ultimately lead to disability.

In order to stop the formation of degenerative changes, it is necessary to take appropriate measures at the very initial stages. Timely medical intervention significantly reduces the risk of developing the disease.

It is movalis that is designed to reduce pain. It can be found in the form of capsules, suspension, tablets and. The drug should be stored in a dry place
at a temperature of no more than 24 degrees.

Instructions for use

Before taking Movalis tablets at a dosage of 15 mg, you must also pay attention to the type of disease.

The medicine is taken during meals or 15 minutes after. It is important to take into account the fact that the risk of an allergic reaction directly depends on the duration of use and the characteristics of individual tolerance to the drug.

As a rule, at the very first and difficult stages disease, the drug is prescribed in the form of injections.

Indications for use

Quite often, patients go to the pharmacy and ask for “something for their back.” To understand whether treatment is really required, you need to know what this particular medicine is used for and then become familiar with its dosage.

More often than not, clients ask for something for back pain. That is why you need to know exactly what the medicine helps with:

Tablets for sciatica are quite common. It manifests itself in damage to the roots spinal cord. The main signs of radiculitis are dysfunction of motor processes and impaired sensitivity. To date, several of its forms are known;
ankylosing spondylitis, accompanied by loss of joint mobility, tension in the muscles, and an increased level of blood ESR. Mostly occurs in males. The second common name of the pathology is Bekhterev-Strumpell-Marie disease;
rheumatoid arthritis is characterized by damage only small joints. The pathology is caused by an infection that disrupts the immune system. In the most recent stages it is treated with surgical intervention. When the first symptoms appear, painkillers are prescribed. Rheumatoid arthritis manifests itself in general weakness and morning stiffness, pain from prolonged sitting, impaired production of tear and salivary glands, apathy.

Duration of admission

The course of treatment directly depends on the diagnosis and severity of symptoms, personal recommendations of the attending physician and dosage. In most cases, to stop inflammatory process And discomfort, seven days are enough when taking one 7.5 mg tablet. The duration of treatment should be based on the patient’s age, body weight, presence allergic reactions on the components of the tablets, as well as the presence of other diseases.

Often, supporting vitamins are prescribed simultaneously with Movalis, because long-term use may lead to irritation of the gastric mucosa. Also, use together with other drugs, for example, glucocorticosteroid hormones, can cause stomach ulcers.

In any case, the most accurate answer to the question “How long to take movalis tablets” will be answered by a rheumatologist. A special category includes people with gastrointestinal complications, renal and heart failure, diabetes mellitus, and tobacco/alcohol addiction. That is why you need to decide on how many days to take the pills on an individual basis.

Dosage

How much you can take should be judged by the duration of the disease, the nature of the damage, general condition the patient and his age. For example, for teenagers the maximum permissible dose equals 0.25 mg/kg. Injections are useful at the most acute stages.

You can determine how to take it correctly based on the diagnosis made by a specialist. So, in the case of arthrosis, 7.5 mg is required; in especially difficult cases, the dosage is increased to 15 mg. In the case of ankylosing spondylitis and rheumatoid arthritis, the medicine is taken in doses of at least 15 mg per day. After the condition improves, the dose is reduced.

It should also be said that patients with impaired renal function and undergoing hemodialysis should take Movalis in a dosage of no more than 7.5 milligrams to avoid complications.

It is forbidden to take Movalis:

teenagers under fifteen years of age;
pregnant and breastfeeding women;
with exacerbations of the duodenum and ulcers;
for kidney and liver diseases, as well as cerebrovascular disease.

It should also be noted that in patients with clinically stable liver cirrhosis, dosage reduction is not necessary.

The appearance of irritations on the skin should alert the rheumatologist. In this option, a complete replacement is recommended medicine to another, more suitable one.

If the dosage is exceeded, anemia, changes in the number of blood leukocytes, severe headaches and anaphylactic reactions occur. Most serious consequence is internal bleeding gastrointestinal tract, vomiting and bloating.

On at the moment There is no antidote, so if the above symptoms occur, urgent gastric lavage is required. It is strongly recommended that you only get specific information about how much you can drink from a qualified doctor.

Composition of the drug

The composition of the tablet will be useful at the stage of selecting the necessary medicine. The buyer can immediately determine whether it suits him or not. For example, for people with lactose intolerance, this medicine is strictly prohibited.

The drug contains the following components:

lactose;
sodium citrate;
colloidal silicon dioxide;
povidone;
magnesium stearate.

This remedy is successfully supplemented with Milgamma and Mydocalm. Complex therapy of the musculoskeletal system is often supported by Movalis.

Tablets or injections, which is better?

The choice of one or another dosage form ultimately depends on the attending physician. The main emphasis will be on the painfulness of the disease. The most common of these are tablets and injections.
The first ones are sold, as a rule, in a box of twenty tablets of 15 mg each. Medicines are sold only by prescription. Long-term use in tablet form can lead to complications in the gastrointestinal tract.

Movalis in injections relieves inflammation more effectively and quickly than tablets and is used in the first few days of treatment (usually no longer than four). The drug is quite actively absorbed into the blood and begins to have an active effect within the first minutes.

The action of its main component, meloxicam, is activated in plasma. The drug is administered subcutaneously and only into the muscle. As practice shows, Movalis injections lead to rapid recovery and eliminate all pain.

In any case, when the task is set which is better than movalis tablets or injections, you should remember about the tolerability of the components and the loads to which the entire body will subsequently be subjected.

Analogs of movalis in tablets

Quite often, the reason for replacing a drug with an analogue is the desire to buy cheaper. This is understandable, since the high cost (approximately 500 rubles for 10 tablets) significantly reduces the treatment time, and therefore its quality.

The resulting low price for the substitute is explained by the fact that it took a lot of time to create, test and advertising campaign The investment is not as big as for the original. With all this, the domestic sample, just like the original, contains a base substance - meloxicam. Relatively inexpensive, the analogue still undergoes full quality and efficiency control.

There is a list of popular drug analogues, among them you can find:

amelatex;
arthrozan;
mataren;
bi-xicam;
liberum;
melbeck
melox;
mesipol.

Although the drug is well tolerated in most cases, it should still be used with caution. The search for a suitable generic is carried out by a specialist who will fully take into account the composition and compare it with the patient’s individual tolerance.

Regarding the impact on the ability to drive a car, no studies have been conducted on generics and originals. Due to this fact, drivers with a high degree of fatigue, slight impairment of coordination and vision should give up driving on the road at the time of therapy.

Selective anti-inflammatory agent. Cups pathological process directly at the site of inflammation and causes fewer side effects than other NSAID drugs. It is used as a means of symptomatic therapy, mainly for rheumatological diseases. Contraindicated in patients under 18 years of age.

Dosage form

The medicine Movalis is a product of the pharmaceutical company Boehringer Ingelheim (Austria). Available in several dosage forms:

Tablets 7.5 mg and 15 mg.
Rectal suppositories 7.5 mg and 15 mg.
Injections for injections in 1.5 ml ampoules.
Suspension for oral administration.

The choice of dosage form always remains with the attending physician, who will be able to select the dose of the medicine depending on the severity of the disease, diagnosis, and characteristics of the patient’s body.

Description and composition

Movalis is a non-steroidal anti-inflammatory drug based on. The drug is often used in the treatment of degenerative diseases affecting the musculoskeletal system. motor system person. The main principle of action of the medicine is to relieve pain and reduce the inflammatory process. Movalis is a drug from the group of phenolic acids. The medicine is often used in the treatment of diseases such as rheumatoid arthritis, osteoarthritis, osteochondrosis and others. Based on the reviews left on various forums, we can conclude that Movalis is one of effective drugs, but at the same time it has many contraindications, so it must be used correctly and only as prescribed by a doctor.

Pharmacological group

Movalis from the group of non-steroidal anti-inflammatory drugs has pronounced anti-inflammatory, analgesic and antipyretic properties. Often used to treat diseases of inflammatory origin. The properties of the drug are determined by its composition, which contains. This component reacts with prostaglandins, thereby eliminating pain and inflammation.

Movalis belongs to a new generation of drugs, has a smaller list of contraindications, but is not inferior in effectiveness to its analogues. The advantage of the drug is that this drug is a COX-2 inhibitor, which allows it not to have any negative effect on the body, acting only in the area of inflammation. Unlike others similar drugs From the group of non-steroids, Movalis inhibits platelet aggregation.

The bioavailability of the drug, regardless of the release form, is practically the same, but the fastest effect of the drug can be obtained when using ampoules for intravenous or intramuscular administration. The process of drug metabolism occurs in the liver. The drug is removed from the body 20 hours after use.

Indications for use

The drug Movalis can be used for almost all diseases of the musculoskeletal system, which are accompanied by pain and an inflammatory reaction.

For adults

The main indications for prescribing the drug may be the following diseases:

osteoarthritis;
osteochondrosis of the cervical, thoracic or lumbar region spine;
Bekhterev's disease;
rheumatoid arthritis.

Other diseases with severe pain syndrome may also be indications for the use of the drug.

For children

Movalis is contraindicated in children under 14 years of age, therefore there is no information about the indications, as well as the doses of the drug in the instructions.

During pregnancy, Movalis in any form or dose is contraindicated. Moreover, taking this drug can provoke pathologies in the development of the fetus, provoke a miscarriage early stages or preterm labor in the late trimesters.

Contraindications

Movalis is a potent drug, so it has enough wide list contraindications.

heart failure;
bronchial asthma;
intolerance to the composition;
ulcerative intestinal lesions;
age up to 14 and after 80 years;
pregnancy period.

Applications and dosages

The drug Movalis can be prescribed only to adults and only to those who have no contraindications to it. IN acute period illness, the doctor may prescribe injections with the drug, a course of 3–4 days. When the pain decreases, the patient can switch to tablets or rectal suppositories.

After intramuscular or intravenous injection, the effect of the drug is observed after 30 minutes and lasts for 6 hours. Regardless of the diagnosis, stage of the disease and symptoms, the daily dose of the drug should not exceed 7.5 - 15 mg.

For adults

The dosage of the drug is determined by the doctor individually for each patient.

Injection ampoules are prescribed only once a day at a dose of 7.5 or 15 mg. The dose is determined by the attending physician. Duration of administration is 2–3 days, then the patient is transferred to tablets or suppositories.
Movalis tablets can be used 2 times a day, 7.5 or 15 mg.
Suppositories of the drug are administered into the rectum before bedtime 1 time per day.

The average treatment course is 10 – 28 days.

For children

For pregnant women and during lactation

During pregnancy, as well as during lactation, the drug cannot be used.

Side effects

Movalis has a fairly large list of contraindications, but all of them are too rare and only if the recommended doses of the drug are not followed or there is a history of contraindications. In practice, the most common side effects are:

heart rhythm disturbance;
headache;
nausea, ;
skin rash;
blood pressure surges;
swelling of the limbs.

Patient complaints about such symptoms are a reason to discontinue the drug or reduce the dose of the drug.

Interaction with other drugs

Taking Movalis together with other drugs may cause unwanted reaction body, so if the patient is taking any other medications, the doctor should be informed about this.

Taking diuretics and Movalis increases the risk of developing kidney failure or dehydration.

special instructions

Persons with a history of serious illnesses Gastrointestinal tract, kidneys, liver or heart, can take the drug in minimal dosages and only under the supervision of medical specialists.
At long-term use When taking the drug, you need to monitor your kidney and liver function and take laboratory tests of urine and blood.

Analogues

The following medications can be used instead of Movalis:

is a complete analogue of the drug Movalis. In the pharmacy the drug comes in injections, tablets and suppositories. It can be prescribed to patients over 15 years of age. Contraindicated in pregnant and breastfeeding women, as well as in patients planning to conceive.
Artrum belongs to non-steroidal anti-inflammatory drugs. The drug contains as an active ingredient. It is commercially available in long-acting tablets, gels, suppositories, injection solution. The medication is taken for pathologies of the musculoskeletal system of an inflammatory and degenerative nature, to relieve pain of various origins. Artrum can be prescribed to patients over 15 years of age, including in the first and second trimester of pregnancy.
belongs to Movalis substitutes in the therapeutic group. The medicine contains as an active ingredient. In the pharmacy, the medicine comes in the form of regular and dissolving tablets, oral suspension, and gel. The drug can be prescribed to children whose weight has reached 7 kg.
contains as an active component. The drug is available in rectal suppositories, gel, injections, transdermal patches, and tablets. The medication is recommended as an analgesic for pathologies of the locomotor system, for hepatic and renal colic, migraine pain, after injuries and surgical treatment. According to strict indications, it can be used up to.

Overdose

If the prescribed doses of the drug are not observed, there is a high risk of developing overdose symptoms:

nausea, ;
fainting;
drowsiness;
increased risk of intestinal bleeding.

If such symptoms appear, you should seek medical help as soon as possible.

Storage conditions

When storing the drug, it is necessary to limit access to light and sunlight. Optimal temperature drug 25 degrees. The shelf life of the medicine is indicated on the packaging and is 5 years from the date of release.

Price

The cost of the medicine is on average 677 rubles. Prices range from 452 to 1150 rubles.